Fine-mapping of IL16 Gene and Prostate Cancer Risk in African Americans

Overview

Journal Cancer Epidemiol Biomarkers Prev

Specialties Biochemistry
Oncology
Public Health

Date 2012 Aug 28

PMID 22923025

Citations 12

Authors

Ken Batai

Ebony Shah

Adam B Murphy

Jennifer Newsome

Maria Ruden

Chiledum Ahaghotu

Rick A Kittles

Affiliations

Soon will be listed here.

Abstract

Background: Prostate cancer is the most common type of cancer among men in the United States, and its incidence and mortality rates are disproportionate among ethnic groups. Although genome-wide association studies of European descents have identified candidate loci associated with prostate cancer risk, including a variant in IL16, replication studies in African Americans (AA) have been inconsistent. Here we explore single-nucleotide polymorphism (SNP) variation in IL16 in AAs and test for association with prostate cancer.

Methods: Association tests were conducted for 2,257 genotyped and imputed SNPs spanning IL16 in 605 AA prostate cancer cases and controls from Washington, D.C. Eleven of them were also genotyped in a replication population of 1,093 AAs from Chicago. We tested for allelic association adjusting for age, global and local West African ancestry.

Results: Analyses of genotyped and imputed SNPs revealed that a cluster of IL16 SNPs were significantly associated with prostate cancer risk. The strongest association was found at rs7175701 (P = 9.8 × 10(-8)). In the Chicago population, another SNP (rs11556218) was associated with prostate cancer risk (P = 0.01). In the pooled analysis, we identified three independent loci within IL16 that were associated with prostate cancer risk. SNP expression quantitative trait loci analyses revealed that rs7175701 is predicted to influence the expression of IL16 and other cancer-related genes.

Conclusion: Our study provides evidence that IL16 polymorphisms play a role in prostate cancer susceptibility among AAs.

Impact: Our findings are significant given that there has been limited focus on the role of IL16 genetic polymorphisms on prostate cancer risk in AAs.

Citing Articles

Novel biomarkers and drug correlations of non-canonical WNT signaling in prostate and breast cancer.

Huang Y, Fan M, Liu Y, Jiang X, Du K, Wu A Discov Oncol. 2024; 15(1):511.

PMID: 39347881 PMC: 11442966. DOI: 10.1007/s12672-024-01394-2.

The role of proinflammatory cytokines and CXC chemokines (CXCL1-CXCL16) in the progression of prostate cancer: insights on their therapeutic management.

Ullah A, Jiao W, Shen B Cell Mol Biol Lett. 2024; 29(1):73.

PMID: 38745115 PMC: 11094955. DOI: 10.1186/s11658-024-00591-9.

Association of Cytokine Gene Polymorphisms with Prostate Cancer Risk from a Study in Central China.

Xu S, Hu Y, Zhang L, Yue S, Zhang L, Liang C Contrast Media Mol Imaging. 2022; 2022:1259009.

PMID: 36034203 PMC: 9392598. DOI: 10.1155/2022/1259009.

Risk Signature of Cancer-Associated Fibroblast-Secreted Cytokines Associates With Clinical Outcomes of Breast Cancer.

Sun C, Wang S, Zhang Y, Yang F, Zeng T, Meng F Front Oncol. 2021; 11:628677.

PMID: 34395236 PMC: 8356635. DOI: 10.3389/fonc.2021.628677.

Association of functional polymorphisms with cancer and cardiovascular disease: a meta-analysis.

de Souza V, de Alencar J, Tiaki Tiyo B, Alves H, Vendramini E, Maria Sell A Oncotarget. 2020; 11(36):3405-3417.

PMID: 32934782 PMC: 7486693. DOI: 10.18632/oncotarget.27715.

References

Scharer C, McCabe C, Ali-Seyed M, Berger M, Bulyk M, Moreno C . Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res. 2009; 69(2):709-17. PMC: 2629396. DOI: 10.1158/0008-5472.CAN-08-3415. View

Lin W, Karin M . A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007; 117(5):1175-83. PMC: 1857251. DOI: 10.1172/JCI31537. View

Teo Y, Small K, Kwiatkowski D . Methodological challenges of genome-wide association analysis in Africa. Nat Rev Genet. 2010; 11(2):149-60. PMC: 3769612. DOI: 10.1038/nrg2731. View

Need A, Goldstein D . Next generation disparities in human genomics: concerns and remedies. Trends Genet. 2009; 25(11):489-94. DOI: 10.1016/j.tig.2009.09.012. View

Ioannidis J, Thomas G, Daly M . Validating, augmenting and refining genome-wide association signals. Nat Rev Genet. 2009; 10(5):318-29. PMC: 7877552. DOI: 10.1038/nrg2544. View

Nelson W, De Marzo A, Isaacs W . Prostate cancer. N Engl J Med. 2003; 349(4):366-81. DOI: 10.1056/NEJMra021562. View

Okobia M, Zmuda J, Ferrell R, Patrick A, Bunker C . Chromosome 8q24 variants are associated with prostate cancer risk in a high risk population of African ancestry. Prostate. 2011; 71(10):1054-63. PMC: 4422491. DOI: 10.1002/pros.21320. View

Landi D, Gemignani F, Barale R, Landi S . A catalog of polymorphisms falling in microRNA-binding regions of cancer genes. DNA Cell Biol. 2007; 27(1):35-43. DOI: 10.1089/dna.2007.0650. View

Kundu J, Surh Y . Inflammation: gearing the journey to cancer. Mutat Res. 2008; 659(1-2):15-30. DOI: 10.1016/j.mrrev.2008.03.002. View

10.

Pritchard J, Stephens M, Donnelly P . Inference of population structure using multilocus genotype data. Genetics. 2000; 155(2):945-59. PMC: 1461096. DOI: 10.1093/genetics/155.2.945. View

11.

Kovacs E . The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy. Biomed Pharmacother. 2001; 55(2):111-6. DOI: 10.1016/s0753-3322(00)00023-8. View

12.

Falush D, Stephens M, Pritchard J . Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics. 2003; 164(4):1567-87. PMC: 1462648. DOI: 10.1093/genetics/164.4.1567. View

13.

Bonilla C, Hooker S, Mason T, Bock C, Kittles R . Prostate cancer susceptibility Loci identified on chromosome 12 in African Americans. PLoS One. 2011; 6(2):e16044. PMC: 3040176. DOI: 10.1371/journal.pone.0016044. View

14.

De Marzo A, Platz E, Sutcliffe S, Xu J, Gronberg H, Drake C . Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007; 7(4):256-69. PMC: 3552388. DOI: 10.1038/nrc2090. View

15.

Howie B, Marchini J, Stephens M . Genotype imputation with thousands of genomes. G3 (Bethesda). 2012; 1(6):457-70. PMC: 3276165. DOI: 10.1534/g3.111.001198. View

16.

Gudmundsson J, Sulem P, Gudbjartsson D, Blondal T, Gylfason A, Agnarsson B . Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet. 2009; 41(10):1122-6. PMC: 3562712. DOI: 10.1038/ng.448. View

17.

Asadullah K, Gellrich S, Hanneken S, Hansen-Hagge T, Docke W, Volk H . IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression. Exp Dermatol. 2000; 9(4):248-51. DOI: 10.1034/j.1600-0625.2000.009004248.x. View

18.

FitzGerald L, Kwon E, Conomos M, Kolb S, Holt S, Levine D . Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011; 20(6):1196-203. PMC: 3111761. DOI: 10.1158/1055-9965.EPI-10-1299. View

19.

Hooker S, Hernandez W, Chen H, Robbins C, Torres J, Ahaghotu C . Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans. Prostate. 2009; 70(3):270-5. DOI: 10.1002/pros.21061. View

20.

Barnholtz-Sloan J, Raska P, Rebbeck T, Millikan R . Replication of GWAS "Hits" by Race for Breast and Prostate Cancers in European Americans and African Americans. Front Genet. 2012; 2:37. PMC: 3268591. DOI: 10.3389/fgene.2011.00037. View